BiondVax Receives Additional Grant Approval

Israel’s National Authority for Technological Innovation to fund 40% of additional $0.9M budget towards Universal Flu Vaccine

NESS ZIONA, ISRAEL, February 18, 2016 -BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV) announced today that the National Authority for Technological Innovation (NATI), formerly known as the Office of the Chief Scientist, agreed to fund up to 40% of a NIS 3.6 million (US$920,000) project towards ongoing development of the Company’s Universal Flu Vaccine.Currently undergoing late Phase 2 clinical trials, BiondVax’s vaccine has shown significantly increased effectiveness against multiple seasonal and pandemic flu strains when compared to today’s existing flu vaccines. With today’s grant approval, NATI has, since 2006, granted $5.5M to BiondVax. The non-dilutive grants are repayable from royalties generated from future sales of BiondVax’s vaccine, once available on the market.Ron Babecoff, CEO of BiondVax commented, “The continued support of our program by NATI represents a strong and ongoing vote of confidence in BiondVax and what we are aiming to achieve. They were impressed with the positive results from our five completed clinical trials to-date, and strongly support our current and planned activities.”About BiondVax Pharmaceuticals Ltd.BiondVax is a biopharmaceutical company developing a universal flu vaccine. The vaccine is designed to provide multi-season protection against most seasonal and pandemic human influenza virus strains. BiondVax’s proprietary technology utilizes a unique combination of conserved and common peptides from influenza virus proteins, activating both arms of the immune system for a cross-protecting and long-lasting effect. BiondVax is traded on NASDAQ: BVXV and TASE: BVXV. For more information, please visit www.biondvax.com.

BiondVax Receives a Confirmation for a Grant of 4.87 million NIS from the Office of the Chief Scientist

The budget is intended for the Continued Clinical Program of the Universal Influenza Vaccine of the Company The Chief Scientist Demonstrates His Continued Confidence, Granting BiondVax NIS 15.7 million Nes Ziona, Israel – 8 September 2014 – BiondVax Pharmaceuticals Ltd. (TASE: BNDX), which is developing the Universal Flu Vaccine, today announced that it has been awarded a sum of 4.87 million NIS by the Chief Scientist in the Ministry of Economy (OCS) for the continued development of BiondVax's Universal Influenza Vaccine in advanced clinical trials. The grant is awarded in accordance with the Israeli law to promote research and development in the industry.The grant approved by OCS will be used to promote the company's effort towards a phase 3 trial with its Universal Vaccine. In addition, the funds will be used for improvements in the manufacturing process and preparation for its scale up, activities which will contribute significantly to its commercialization.Ron Babecoff, BiondVax's CEO's said today: "We are proud for been awarded yet another grant by the OCS. In the last years OCS has expressed its repeated trust in our Universal Vaccine program and we enjoyed considerable financial support that led to our clinical successes. This is another step in our journey to approve the first Universal Flu Vaccine".